Is Kala Pharmaceuticals Stock a Good Investment?
Kala Pharmaceuticals Investment Advice | KALA |
- Examine Kala Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Kala Pharmaceuticals' leadership team and their track record. Good management can help Kala Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Kala Pharmaceuticals' business and its evolving consumer preferences.
- Compare Kala Pharmaceuticals' performance and market position to its competitors. Analyze how Kala Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Kala Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Kala Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Kala Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Kala Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Kala Pharmaceuticals Stock
Researching Kala Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 48.0% of the company shares are owned by institutional investors. The book value of Kala Pharmaceuticals was now reported as 2.72. The company recorded a loss per share of 11.67. Kala Pharmaceuticals had not issued any dividends in recent years. The entity had 1:50 split on the 21st of October 2022.
To determine if Kala Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kala Pharmaceuticals' research are outlined below:
| Kala Pharmaceuticals had very high historical volatility over the last 90 days | |
| Kala Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.2 M) with profit before overhead, payroll, taxes, and interest of 1.33 M. | |
| Kala Pharmaceuticals currently holds about 44.57 M in cash with (27.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 30.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kala Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: KALA BIO Issues Earnings Results |
Kala Pharmaceuticals Quarterly Accounts Payable |
|
Kala Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kala Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kala Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Kala Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Kala Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-29 | 2023-12-31 | -3.62 | -3.18 | 0.44 | 12 | ||
2024-11-11 | 2024-09-30 | -2.43 | -1.9341 | 0.4959 | 20 | ||
2023-08-04 | 2023-06-30 | -3.19 | -4.36 | -1.17 | 36 | ||
2024-08-06 | 2024-06-30 | -4.4 | -3.16 | 1.24 | 28 | ||
2023-11-13 | 2023-09-30 | -2.15 | -3.41 | -1.26 | 58 | ||
2024-05-14 | 2024-03-31 | -2.89 | -4.19 | -1.3 | 44 | ||
2023-03-03 | 2022-12-31 | -6.55 | -7.97 | -1.42 | 21 | ||
2023-05-09 | 2023-03-31 | -4.52 | -6.99 | -2.47 | 54 |
Know Kala Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kala Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kala Pharmaceuticals backward and forwards among themselves. Kala Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kala Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sassicaia Capital Advisers Llc | 2024-06-30 | 12 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 K | Tower Research Capital Llc | 2024-06-30 | 1.9 K | Covestor Ltd | 2024-06-30 | 1 K | Banque Cantonale Vaudoise | 2024-06-30 | 808 | Compagnie Lombard, Odier Sca | 2024-09-30 | 400 | Citigroup Inc | 2024-06-30 | 296 | Cwm, Llc Duplicate | 2024-06-30 | 200 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 120 | Baker Bros Advisors Lp | 2024-09-30 | 891.3 K | Sr One Capital Management, Lp | 2024-06-30 | 443.7 K |
Kala Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.64 M.Market Cap |
|
Kala Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.75) | (0.79) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.75) | (0.79) | |
| Return On Equity | (5.62) | (5.34) |
Determining Kala Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Kala Pharmaceuticals is a good buy. For example, gross profit margin measures Kala Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kala Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Kala Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kala Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Kala Pharmaceuticals' management manipulating its earnings.
Evaluate Kala Pharmaceuticals' management efficiency
Kala Pharmaceuticals has return on total asset (ROA) of (0.4025) % which means that it has lost $0.4025 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4811) %, meaning that it created substantial loss on money invested by shareholders. Kala Pharmaceuticals' management efficiency ratios could be used to measure how well Kala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.79. In addition to that, Return On Capital Employed is expected to decline to -0.86. At present, Kala Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 98.6 M, whereas Total Assets are forecasted to decline to about 53.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.09 | 2.93 | |
| Tangible Book Value Per Share | 3.09 | 2.93 | |
| Enterprise Value Over EBITDA | (0.07) | (0.07) | |
| Price Book Value Ratio | 2.27 | 1.81 | |
| Enterprise Value Multiple | (0.07) | (0.07) | |
| Price Fair Value | 2.27 | 1.81 | |
| Enterprise Value | 27.4 M | 29.6 M |
The decision-making processes within Kala Pharmaceuticals are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta (2.14) |
Basic technical analysis of Kala Stock
As of the 21st of November, Kala Pharmaceuticals secures the Mean Deviation of 2.28, downside deviation of 2.21, and Risk Adjusted Performance of 0.031. Kala Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Kala Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kala Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kala Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kala Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kala Pharmaceuticals' Outstanding Corporate Bonds
Kala Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kala Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kala bonds can be classified according to their maturity, which is the date when Kala Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Kala Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Kala Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.031 | |||
| Market Risk Adjusted Performance | 0.2892 | |||
| Mean Deviation | 2.28 | |||
| Semi Deviation | 2.11 | |||
| Downside Deviation | 2.21 | |||
| Coefficient Of Variation | 3221.44 | |||
| Standard Deviation | 3.17 | |||
| Variance | 10.05 | |||
| Information Ratio | 9.0E-4 | |||
| Jensen Alpha | 0.0614 | |||
| Total Risk Alpha | (0.27) | |||
| Sortino Ratio | 0.0014 | |||
| Treynor Ratio | 0.2792 | |||
| Maximum Drawdown | 15.25 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 6.54 | |||
| Downside Variance | 4.9 | |||
| Semi Variance | 4.44 | |||
| Expected Short fall | (3.23) | |||
| Skewness | 1.44 | |||
| Kurtosis | 2.42 |
| Risk Adjusted Performance | 0.031 | |||
| Market Risk Adjusted Performance | 0.2892 | |||
| Mean Deviation | 2.28 | |||
| Semi Deviation | 2.11 | |||
| Downside Deviation | 2.21 | |||
| Coefficient Of Variation | 3221.44 | |||
| Standard Deviation | 3.17 | |||
| Variance | 10.05 | |||
| Information Ratio | 9.0E-4 | |||
| Jensen Alpha | 0.0614 | |||
| Total Risk Alpha | (0.27) | |||
| Sortino Ratio | 0.0014 | |||
| Treynor Ratio | 0.2792 | |||
| Maximum Drawdown | 15.25 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 6.54 | |||
| Downside Variance | 4.9 | |||
| Semi Variance | 4.44 | |||
| Expected Short fall | (3.23) | |||
| Skewness | 1.44 | |||
| Kurtosis | 2.42 |
Consider Kala Pharmaceuticals' intraday indicators
Kala Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kala Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Kala Pharmaceuticals Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 25th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of September 2024 Other Reports | ViewVerify |
Kala Stock media impact
Far too much social signal, news, headlines, and media speculation about Kala Pharmaceuticals that are available to investors today. That information is available publicly through Kala media outlets and privately through word of mouth or via Kala internal channels. However, regardless of the origin, that massive amount of Kala data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kala Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kala Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kala Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kala Pharmaceuticals alpha.
Kala Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kala Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kala Pharmaceuticals Corporate Management
| CPA CPA | CFO Treasurer | Profile | |
| Jill Steier | Executive Communications | Profile | |
| Carl Rennie | Executive Management | Profile | |
| MBA JD | Chief Officer | Profile | |
| Kim Brazzell | Chief Medical Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.67) | Quarterly Revenue Growth (1.00) | Return On Assets (0.40) | Return On Equity (2.48) |
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Kala Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.